Over the past decade, significant advances in evidence-based medicine have fundamentally transformed the therapeutic landscape for hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.